Treatment with botulinum toxin type B for upper-limb spasticity

Allison Brashear, Anita L. McAfee, Elizabeth R. Kuhn, Walter T. Ambrosius

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective: To determine if botulinum toxin type B (Myo-Bloc) decreases spasticity. Design: Investigator-initiated trial, open-label, single-treatment session. Setting: Single site. Participants: Ten patients with stable upper-limb spasticity and an Ashworth Scale score of 2 or higher at the elbow, wrist, and fingers. Interventions: Total dose of 10, 000U of botulinum toxin type B injected into 5 major muscles. Main Outcome Measures: The Ashworth Scale, goniometry, and functional assessments were performed at injection and weeks 4, 8, and 12. The principal investigator (PI) global assessment of change (GAC) and the patient GAC were done at weeks 4, 8, and 12 postinjection. The safety of the procedure was measured by adverse events and vital signs. Results: Improvements in Ashworth Scale scores were observed at weeks 4, 8, and 12 postinjection. At week 4, the mean changes (in Ashworth score) were elbow, -1.0 (P=.016); wrist, -1.7 (P=.004); finger, -1.35 (P=.02); at week 8: elbow, -.83 (P=.016); wrist, -1.00 (P=.016); finger, -.94 (P=.08); and at week 12: elbow, -.61 (P=.07); wrist, - 1.00 (P=.016); and finger, -.89 (P=.10). The PI GAC improved at all visits. Nine of the 10 subjects reported dry mouth at week 4, with resolution by week 12. No changes were seen on the functional measures. Conclusions: Botulinum toxin type B may be useful in treatment of spasticity.

Original languageEnglish (US)
Pages (from-to)103-107
Number of pages5
JournalArchives of Physical Medicine and Rehabilitation
Volume84
Issue number1
DOIs
StatePublished - Jan 2003
Externally publishedYes

Fingerprint

Elbow
Wrist
Upper Extremity
Fingers
Research Personnel
Vital Signs
Therapeutics
Mouth
Outcome Assessment (Health Care)
Safety
Muscles
Injections
rimabotulinumtoxinB

Keywords

  • Botulinum toxins
  • Rehabilitation
  • Spasticity
  • Stroke

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation

Cite this

Treatment with botulinum toxin type B for upper-limb spasticity. / Brashear, Allison; McAfee, Anita L.; Kuhn, Elizabeth R.; Ambrosius, Walter T.

In: Archives of Physical Medicine and Rehabilitation, Vol. 84, No. 1, 01.2003, p. 103-107.

Research output: Contribution to journalArticle

Brashear, Allison ; McAfee, Anita L. ; Kuhn, Elizabeth R. ; Ambrosius, Walter T. / Treatment with botulinum toxin type B for upper-limb spasticity. In: Archives of Physical Medicine and Rehabilitation. 2003 ; Vol. 84, No. 1. pp. 103-107.
@article{39c86c326305452eaad795c751fa2122,
title = "Treatment with botulinum toxin type B for upper-limb spasticity",
abstract = "Objective: To determine if botulinum toxin type B (Myo-Bloc) decreases spasticity. Design: Investigator-initiated trial, open-label, single-treatment session. Setting: Single site. Participants: Ten patients with stable upper-limb spasticity and an Ashworth Scale score of 2 or higher at the elbow, wrist, and fingers. Interventions: Total dose of 10, 000U of botulinum toxin type B injected into 5 major muscles. Main Outcome Measures: The Ashworth Scale, goniometry, and functional assessments were performed at injection and weeks 4, 8, and 12. The principal investigator (PI) global assessment of change (GAC) and the patient GAC were done at weeks 4, 8, and 12 postinjection. The safety of the procedure was measured by adverse events and vital signs. Results: Improvements in Ashworth Scale scores were observed at weeks 4, 8, and 12 postinjection. At week 4, the mean changes (in Ashworth score) were elbow, -1.0 (P=.016); wrist, -1.7 (P=.004); finger, -1.35 (P=.02); at week 8: elbow, -.83 (P=.016); wrist, -1.00 (P=.016); finger, -.94 (P=.08); and at week 12: elbow, -.61 (P=.07); wrist, - 1.00 (P=.016); and finger, -.89 (P=.10). The PI GAC improved at all visits. Nine of the 10 subjects reported dry mouth at week 4, with resolution by week 12. No changes were seen on the functional measures. Conclusions: Botulinum toxin type B may be useful in treatment of spasticity.",
keywords = "Botulinum toxins, Rehabilitation, Spasticity, Stroke",
author = "Allison Brashear and McAfee, {Anita L.} and Kuhn, {Elizabeth R.} and Ambrosius, {Walter T.}",
year = "2003",
month = "1",
doi = "10.1053/apmr.2003.50070",
language = "English (US)",
volume = "84",
pages = "103--107",
journal = "Archives of Physical Medicine and Rehabilitation",
issn = "0003-9993",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Treatment with botulinum toxin type B for upper-limb spasticity

AU - Brashear, Allison

AU - McAfee, Anita L.

AU - Kuhn, Elizabeth R.

AU - Ambrosius, Walter T.

PY - 2003/1

Y1 - 2003/1

N2 - Objective: To determine if botulinum toxin type B (Myo-Bloc) decreases spasticity. Design: Investigator-initiated trial, open-label, single-treatment session. Setting: Single site. Participants: Ten patients with stable upper-limb spasticity and an Ashworth Scale score of 2 or higher at the elbow, wrist, and fingers. Interventions: Total dose of 10, 000U of botulinum toxin type B injected into 5 major muscles. Main Outcome Measures: The Ashworth Scale, goniometry, and functional assessments were performed at injection and weeks 4, 8, and 12. The principal investigator (PI) global assessment of change (GAC) and the patient GAC were done at weeks 4, 8, and 12 postinjection. The safety of the procedure was measured by adverse events and vital signs. Results: Improvements in Ashworth Scale scores were observed at weeks 4, 8, and 12 postinjection. At week 4, the mean changes (in Ashworth score) were elbow, -1.0 (P=.016); wrist, -1.7 (P=.004); finger, -1.35 (P=.02); at week 8: elbow, -.83 (P=.016); wrist, -1.00 (P=.016); finger, -.94 (P=.08); and at week 12: elbow, -.61 (P=.07); wrist, - 1.00 (P=.016); and finger, -.89 (P=.10). The PI GAC improved at all visits. Nine of the 10 subjects reported dry mouth at week 4, with resolution by week 12. No changes were seen on the functional measures. Conclusions: Botulinum toxin type B may be useful in treatment of spasticity.

AB - Objective: To determine if botulinum toxin type B (Myo-Bloc) decreases spasticity. Design: Investigator-initiated trial, open-label, single-treatment session. Setting: Single site. Participants: Ten patients with stable upper-limb spasticity and an Ashworth Scale score of 2 or higher at the elbow, wrist, and fingers. Interventions: Total dose of 10, 000U of botulinum toxin type B injected into 5 major muscles. Main Outcome Measures: The Ashworth Scale, goniometry, and functional assessments were performed at injection and weeks 4, 8, and 12. The principal investigator (PI) global assessment of change (GAC) and the patient GAC were done at weeks 4, 8, and 12 postinjection. The safety of the procedure was measured by adverse events and vital signs. Results: Improvements in Ashworth Scale scores were observed at weeks 4, 8, and 12 postinjection. At week 4, the mean changes (in Ashworth score) were elbow, -1.0 (P=.016); wrist, -1.7 (P=.004); finger, -1.35 (P=.02); at week 8: elbow, -.83 (P=.016); wrist, -1.00 (P=.016); finger, -.94 (P=.08); and at week 12: elbow, -.61 (P=.07); wrist, - 1.00 (P=.016); and finger, -.89 (P=.10). The PI GAC improved at all visits. Nine of the 10 subjects reported dry mouth at week 4, with resolution by week 12. No changes were seen on the functional measures. Conclusions: Botulinum toxin type B may be useful in treatment of spasticity.

KW - Botulinum toxins

KW - Rehabilitation

KW - Spasticity

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0037229964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037229964&partnerID=8YFLogxK

U2 - 10.1053/apmr.2003.50070

DO - 10.1053/apmr.2003.50070

M3 - Article

C2 - 12589629

AN - SCOPUS:0037229964

VL - 84

SP - 103

EP - 107

JO - Archives of Physical Medicine and Rehabilitation

JF - Archives of Physical Medicine and Rehabilitation

SN - 0003-9993

IS - 1

ER -